Table 1.
Clinical characteristics of NPC patients treated with AdE1-LMPpoly T-cells.
| ARMD | N/MRD | |
|---|---|---|
| |
(n = 21) |
(n = 9) |
| Median age in years (range) | 46 (34–68) | 49 (22–66) |
| Sex | ||
| Male | 18 | 8 |
| Female | 2 | 1 |
| Stage on diagnosis | ||
| I | 2 | 2 |
| II | 2 | 1 |
| III | 7 | 4 |
| IVA | 7 | 1 |
| IVB | 1 | 1 |
| IVC | 2 | 0 |
| Median number of lines of chemotherapy before T-cell therapy (range) | 3 (1 to 5) | 2 (1 to 4) |
| History of recurrent NPC | 21 | 7 |
| Disease status at first T-cell infusion | ||
| No radiological disease | 0 | 9 |
| Local recurrence | 11 | 0 |
| Regional nodal recurrence | 6 | 0 |
| Lung metastasis | 9 | 0 |
| Liver metastasis | 5 | 0 |
| Bone metastasis | 5 | 0 |
| Distant nodal metastasis | 4 | 0 |
| Median plasma EBV DNA copies/mLbefore T-cell therapy (range) | 2.3 × 103 (0 to 6.3 × 106) | 0 (0) |
Abbreviations: ARMD, active recurrent/metastatic disease; EBV DNA, Epstein-Barr virus deoxyribonucleic acid; N/MRD, no or minimal residual disease; NPC, nasopharyngeal carcinoma.